Table 1.
Demographic and clinical characteristics of patient in therapeutic efficacy studies to evaluate artemether-lumefantrine or artesunate + sulfadoxine-pyrimethamine in Sudan (2010–2015)
| Drug | Site | Study years | N | Males | Age group | Temperature D0 | Parasite count (/uL), D0 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <5 years | 5–14 years | ≥15 years | |||||||||||||
| N | (%) | N | (%) | N | (%) | N | (%) | Mean | (SD) | Geometric mean | Range | ||||
| AS + SP | Kosti | 2010 | 92 | 57 | (62) | 14 | (15) | 59 | (64) | 19 | (21) | 38.1 | (1) | 26,202 | (5470–90,940) |
| Sennar | 2010 | 97 | 51 | (53) | 5 | (5) | 69 | (71) | 23 | (24) | 38.4 | (0.9) | 13,973 | (1800–71,889) | |
| Gedaref | 2011–12 | 100 | 53 | (53) | 17 | (17) | 52 | (52) | 31 | (31) | 39 | (1.1) | 11,725 | (1600–129,167) | |
| Kassala | 2011 | 75 | 44 | (59) | 24 | (32) | 17 | (23) | 34 | (45) | 38.1 | (0.8) | 5917 | (1020–68,421) | |
| Kosti | 2011 | 98 | 55 | (56) | 17 | (17) | 63 | (64) | 18 | (18) | 38.1 | (1.1) | 14,249 | (3380–88,098) | |
| Sennar | 2011 | 95 | 43 | (44) | 9 | (10) | 71 | (75) | 15 | (16) | 37.9 | (1.2) | 10,592 | (1400–57,910) | |
| Kosti | 2012–13 | 95 | 45 | (47) | 20 | (21) | 58 | (61) | 17 | (18) | 37.1 | (1.1) | 18,541 | (1120–97,143) | |
| Damazin | 2013–14 | 100 | 61 | (61) | 19 | (19) | 67 | (67) | 14 | (14) | 37.7 | (1) | 15,657 | (1460–90,000) | |
| Sennnar | 2013–14 | 88 | 57 | (65) | 9 | (10) | 76 | (86) | 3 | (3) | 37.1 | (0.9) | 8252 | (1140–35,500) | |
| New Halfa | 2013–14 | 80 | 40 | (50) | 14 | (18) | 25 | (31) | 41 | (51) | 38.6 | (1.8) | 12,798 | (2123–116,666) | |
| Gedaref | 2014–15 | 93 | 47 | (51) | 15 | (16) | 58 | (62) | 20 | (22) | 37.6 | (0.9) | 11,165 | (1053–52,319) | |
| AL | Damazin | 2010 | 67 | 32 | (48) | 0 | (0) | 30 | (45) | 37 | (55) | 38.2 | (0.6) | 11,203 | (1675–100,000) |
| Kassala | 2010 | 85 | 57 | (67) | 11 | (13) | 40 | (47) | 34 | (40) | 37.8 | (1) | 11,245 | (1500–97,142) | |
| Kosti | 2012–13 | 101 | 64 | (63) | 7 | (7) | 44 | (44) | 50 | (50) | 38.2 | (0.9) | 5339 | (1000–45,756) | |
| Damazin | 2013 | 98 | 54 | (55) | 11 | (11) | 64 | (65) | 23 | (24) | 38.1 | (0.9) | 12,095 | (3020–70,961) | |
| Kassala | 2013–14 | 84 | 53 | (63) | 12 | (14) | 32 | (38) | 40 | (48) | 38 | (0.7) | 16,226 | (1100–90,000) | |
| Sennar | 2013–14 | 42 | 22 | (52) | 5 | (12) | 26 | (62) | 11 | (26) | 38.5 | (1.2) | 18,695 | (3280–93,939) | |
| Gedaref | 2013–14 | 35 | 26 | (74) | 1 | (3) | 10 | (29) | 24 | (69) | 37.6 | (0.9) | 8524 | (1060–75,000) | |
| Sennar | 2014 | 41 | 22 | (54) | 8 | (20) | 25 | (61) | 8 | (20) | 37.8 | (1.1) | 10,827 | (1040-78,110) | |
| Gedaref | 2014–15 | 42 | 29 | (69) | 7 | (17) | 23 | (55) | 12 | (29) | 37 | (1.1) | 4741 | (1300–14,240) | |
SD standard deviation